Intuitive Surgical FAQ: 2025 Financial Results, Beta Volatility, Infection Control Products, ICD Devices, Catheter Ablation

I'm a procurement manager at a 1,200-person integrated health network. I've managed our surgical capital and supplies budget for eight years, negotiated with more than 30 vendors, and documented every order in our tracking system. This FAQ is the one I would have wanted before I bought our first robotic surgery system. The topics people bundle under 'Intuitive Surgical' are often more confusing than they need to be: financial results, beta volatility, infection control products, ICD devices, and catheter ablation. Here are direct answers from the cost side.

Questions in this guide:

• Which Intuitive Surgical financial results 2025 should I actually use?
• Why does Intuitive Surgical beta volatility show up in procurement research?
• What infection control products do you need for a robotic surgery program?
• Does an ICD device have anything to do with Intuitive Surgical?
• What is catheter ablation, and is it a da Vinci procedure?
• What hidden costs in robotic surgery never appear in the first quote?
• Should I compare robotic systems by list price or total cost per procedure?
• Who should help build the total cost model?

Which Intuitive Surgical financial results 2025 should I use?

Don't look for full-year 2025 results in July 2025. They typically come out in late January 2026. The latest full press release at mid-2025 is Q1 2025, released in April 2025. For context, full-year 2024 revenue was about $8.35 billion, according to Intuitive's Q4 2024 press release. That part is public and easy to verify.

What I actually watch: procedure growth, installed base, and instrument/accessory revenue. Procedure growth tells me how much competitive pressure exists in my local market. Installed base tells me how many surgeons are already trained on the platform. Recurring revenue tells me whether the company can keep funding training and R&D. Do not copy exact numbers from a blog into your board deck. Pull the latest press release from Intuitive's investor relations page.

Source: Intuitive Surgical Q4 2024 earnings press release, January 2025. Verify any 2025 figures on the company's investor relations site before using them internally.

Why does Intuitive Surgical beta volatility matter?

Intuitive Surgical beta volatility is a commonly searched term, but beta is not a product spec. Beta measures how much a stock moves relative to the S&P 500. A beta near 1.0 means the stock tends to move with the market. A beta above 1.0 means it can swing more. Most financial data sites show ISRG beta somewhere in the 1.0 to 1.3 range, depending on daily, weekly, or monthly measurement periods. Source: market data platforms, July 2025; values change.

From a procurement perspective, beta is a stock-market signal, not a vendor evaluation criterion. A lower beta doesn't mean better service. A higher beta doesn't mean the da Vinci system will stop working. I include vendor financial health in risk assessments, but I look at revenue growth, cash flow, and service staffing. Every spreadsheet analysis pointed to a low-beta vendor; something felt off because their service coverage was thin. It turned out that cheap stock movement and cheap service contracts both carry the same problem: you don't notice the risk until you need it.

What infection control products do I need for a robotic surgery system?

Infection control in robotics is not one product. It's a bundle: sterile drapes for the patient cart and arms, camera sleeves, trocar seals, sterile instrument covers, single-use accessories, reprocessing solutions, and the tracking system that proves instruments were cleaned and sterilized within their reuse limits. If your hospital uses instrument tracking software, those modules need to communicate with your OR supply system.

When I audited our 2023 spending on surgical robots, infection-control consumables were about 4% of the total robot-related supply budget. That sounds small. But the cost of one surgical-site infection in readmissions, OR time, and long-term care is far more than a year of sterile consumables. Cutting the infection-control line to save money is the worst TCO move I know.

We didn't have a formal process for tracking how many reprocessing cycles a multi-use instrument had been through. That was a process gap. We caught it in 2024, added a scan step, and the vendor's tracking dashboard finally matched our physical inventory. Don't wait for a sterile-processing audit to teach you this.

Does an ICD device have anything to do with Intuitive Surgical?

Not in product terms. ICD usually stands for implantable cardioverter-defibrillator: a device placed in a patient's chest to monitor the heart and deliver a shock if a dangerous rhythm starts. Intuitive Surgical does not make ICDs. That product category belongs to cardiac-device manufacturers, and it's a separate capital and implant budget.

But in search terms and purchasing, ICD can also be shorthand for infection-control device. That's the exact ambiguity that causes contract mistakes. I once saw an alphabet soup RFQ where 'ICD devices' was placed in the infection-control category and a vendor bid 900-piece lots of sterile covers that had nothing to do with cardiology. Clarify the acronym before you send the request for proposal.

Also, if you're budgeting for an ICD device, include the leads, programmer, remote monitoring service, and replacement plan. The price of the 'box' is only the start.

What is catheter ablation, and is it a da Vinci procedure?

Catheter ablation is a minimally invasive procedure used to treat abnormal heart rhythms. An electrophysiologist guides a thin catheter through a vein or artery into the heart. Then energy, either radiofrequency or cryoablation, creates tiny scars to block faulty electrical signals. It is commonly used for atrial fibrillation, atrial flutter, and other arrhythmias. Source: heart.org guidance, accessed July 2025; verify current information.

Catheter ablation is not done with the da Vinci system. Intuitive's Ion platform is a robotic-assisted endoluminal tool used for lung biopsy and similar procedures, not cardiac ablation. In an operating room budget, these are different service lines. If your capital plan includes both an EP lab upgrade and a robotic surgery program, keep them in separate TCO models. Mixing them only hides utilization problems.

What hidden costs in robotic surgery never appear in the first quote?

Here's the thing: a first quote is a teaser rate, not a total cost. I assumed 'same purchase price' meant similar contract terms between vendors. Didn't verify. Turned out one quote excluded software upgrades, another excluded shipping and installation consumables, and a third put a strict cap on training hours.

Use a checklist with at least these categories:

• Capital equipment and installation including floor load and OR renovation
• Instruments and accessories per case
• Sterile processing and infection-control consumables
• Reprocessing cycle capacity
• Training, proctoring, and surgeon credentialing
• Service, spare parts, and software upgrades
• OR turnover time during the learning curve
• Decommissioning or future trade-in value

When I compared final TCO across vendors, the system with the second-lowest list price ended up the most expensive because its per-case instrument cost was 22% higher. The lowest list price looked attractive—until I added the annual service contract and mandatory operator training renewal.

Should I compare robotic systems by list price or total cost per procedure?

Total cost per procedure. We purchase capital equipment, but we consume it at the procedural level. If a system can do 700 procedures per year and the instrument cost is $300 less per case, that's $210,000 of annual cost difference. That dwarfs most installation and service price differences.

In Q2 2024, I compared final quotes from several vendors side by side over a 5-year horizon. The vendor with the highest base price actually had the lowest 5-year total cost per procedure, because the instrument pricing was predictable and the service contract included all software upgrades. The cheapest base price came with a per-incident service fee that we never noticed until the risk review. Seeing those two projections side by side is what convinced our board to focus on TCO instead of the sticker price.

Look, the numbers said go with the cheaper base price. My gut said the supplier's service staffing was thin. Went with my gut. Turns out the 'cheap' option required a 90-day wait for a spare part. Beta volatility and service volatility are two different kinds of risk.

Who should help build the total cost model?

Surgeons, sterile processing, OR nursing, biomedical engineering, finance, supply chain, and an administrator who can say no. We didn't have a formal cross-functional process for the first system. The third time we replaced a major platform, I finally created a pre-purchase checklist that requires every one of those roles to sign off on the assumptions.

Why this matters: the surgeon cares about control, the nurse cares about turnover time, sterile processing cares about cycle counts, and I care about what each case actually costs. A TCO model built without all of them is a spreadsheet fantasy. That's it.